vs

Side-by-side financial comparison of Dragonfly Energy Holdings Corp. (DFLI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $13.1M, roughly 1.5× Dragonfly Energy Holdings Corp.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -344.9%, a 167.5% gap on every dollar of revenue. On growth, Dragonfly Energy Holdings Corp. posted the faster year-over-year revenue change (6.9% vs -11.5%). Dragonfly Energy Holdings Corp. produced more free cash flow last quarter ($-14.9M vs $-23.1M). Over the past eight quarters, Dragonfly Energy Holdings Corp.'s revenue compounded faster (2.2% CAGR vs -12.2%).

Dragonfly Energy Holdings Corp. is a U.S.-based energy technology company specializing in designing and manufacturing high-performance, sustainable lithium-ion batteries. Its core offerings include deep-cycle batteries for RVs, marine uses, off-grid power systems, and residential energy storage, primarily serving consumer and small industrial renewable energy markets across North America.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

DFLI vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.5× larger
LAB
$19.6M
$13.1M
DFLI
Growing faster (revenue YoY)
DFLI
DFLI
+18.4% gap
DFLI
6.9%
-11.5%
LAB
Higher net margin
LAB
LAB
167.5% more per $
LAB
-177.4%
-344.9%
DFLI
More free cash flow
DFLI
DFLI
$8.2M more FCF
DFLI
$-14.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
DFLI
DFLI
Annualised
DFLI
2.2%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DFLI
DFLI
LAB
LAB
Revenue
$13.1M
$19.6M
Net Profit
$-45.0M
$-34.7M
Gross Margin
18.2%
48.5%
Operating Margin
-78.1%
-168.5%
Net Margin
-344.9%
-177.4%
Revenue YoY
6.9%
-11.5%
Net Profit YoY
-357.6%
-28.8%
EPS (diluted)
$-13.09
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DFLI
DFLI
LAB
LAB
Q4 25
$13.1M
Q3 25
$16.0M
$19.6M
Q2 25
$16.2M
$21.8M
Q1 25
$13.4M
$40.8M
Q4 24
$12.2M
Q3 24
$12.7M
$22.1M
Q2 24
$13.2M
$22.5M
Q1 24
$12.5M
$45.5M
Net Profit
DFLI
DFLI
LAB
LAB
Q4 25
$-45.0M
Q3 25
$-11.1M
$-34.7M
Q2 25
$-7.0M
$-33.5M
Q1 25
$-6.8M
$-26.0M
Q4 24
$-9.8M
Q3 24
$-6.8M
$-26.9M
Q2 24
$-13.6M
$-45.7M
Q1 24
$-10.4M
$-32.2M
Gross Margin
DFLI
DFLI
LAB
LAB
Q4 25
18.2%
Q3 25
29.7%
48.5%
Q2 25
28.3%
48.8%
Q1 25
29.4%
48.4%
Q4 24
20.8%
Q3 24
22.6%
54.9%
Q2 24
24.0%
46.1%
Q1 24
24.4%
53.1%
Operating Margin
DFLI
DFLI
LAB
LAB
Q4 25
-78.1%
Q3 25
-23.7%
-168.5%
Q2 25
-20.2%
-118.1%
Q1 25
-44.3%
-80.8%
Q4 24
-58.5%
Q3 24
-47.4%
-120.9%
Q2 24
-51.1%
-134.5%
Q1 24
-46.7%
-132.2%
Net Margin
DFLI
DFLI
LAB
LAB
Q4 25
-344.9%
Q3 25
-69.3%
-177.4%
Q2 25
-43.3%
-153.7%
Q1 25
-50.9%
-63.8%
Q4 24
-80.6%
Q3 24
-53.3%
-122.0%
Q2 24
-103.2%
-203.3%
Q1 24
-82.9%
-70.6%
EPS (diluted)
DFLI
DFLI
LAB
LAB
Q4 25
$-13.09
Q3 25
$-0.20
$-0.09
Q2 25
$-0.58
$-0.09
Q1 25
$-0.93
$-0.07
Q4 24
$-54.60
Q3 24
$-0.11
$-0.07
Q2 24
$-0.22
$-0.12
Q1 24
$-0.17
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DFLI
DFLI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$18.3M
$129.4M
Total DebtLower is stronger
$19.3M
Stockholders' EquityBook value
$11.5M
$399.7M
Total Assets
$86.5M
$539.6M
Debt / EquityLower = less leverage
1.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DFLI
DFLI
LAB
LAB
Q4 25
$18.3M
Q3 25
$3.8M
$129.4M
Q2 25
$2.7M
$158.6M
Q1 25
$2.5M
$150.9M
Q4 24
$4.8M
Q3 24
$8.0M
$210.6M
Q2 24
$4.7M
$269.8M
Q1 24
$8.5M
$287.1M
Total Debt
DFLI
DFLI
LAB
LAB
Q4 25
$19.3M
Q3 25
$97.1M
Q2 25
$93.2M
Q1 25
$89.5M
Q4 24
$85.9M
Q3 24
$82.4M
$55.2M
Q2 24
$80.4M
$55.1M
Q1 24
$77.1M
$55.0M
Stockholders' Equity
DFLI
DFLI
LAB
LAB
Q4 25
$11.5M
Q3 25
$-21.6M
$399.7M
Q2 25
$-16.6M
$424.5M
Q1 25
$-15.6M
$454.6M
Q4 24
$-9.4M
Q3 24
$-297.0K
$489.3M
Q2 24
$5.3M
$510.3M
Q1 24
$17.8M
$577.3M
Total Assets
DFLI
DFLI
LAB
LAB
Q4 25
$86.5M
Q3 25
$73.8M
$539.6M
Q2 25
$71.8M
$557.0M
Q1 25
$74.2M
$579.6M
Q4 24
$75.2M
Q3 24
$83.9M
$681.5M
Q2 24
$85.0M
$708.7M
Q1 24
$88.4M
$777.7M
Debt / Equity
DFLI
DFLI
LAB
LAB
Q4 25
1.68×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
15.27×
0.11×
Q1 24
4.33×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DFLI
DFLI
LAB
LAB
Operating Cash FlowLast quarter
$-14.7M
$-22.2M
Free Cash FlowOCF − Capex
$-14.9M
$-23.1M
FCF MarginFCF / Revenue
-113.8%
-118.1%
Capex IntensityCapex / Revenue
1.1%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DFLI
DFLI
LAB
LAB
Q4 25
$-14.7M
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-4.5M
$-30.3M
Q4 24
$-2.5M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-3.4M
$-62.5M
Free Cash Flow
DFLI
DFLI
LAB
LAB
Q4 25
$-14.9M
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-5.3M
$-35.3M
Q4 24
$-3.5M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-4.2M
$-63.3M
FCF Margin
DFLI
DFLI
LAB
LAB
Q4 25
-113.8%
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-39.6%
-86.6%
Q4 24
-28.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-33.7%
-138.9%
Capex Intensity
DFLI
DFLI
LAB
LAB
Q4 25
1.1%
Q3 25
4.5%
Q2 25
8.7%
Q1 25
5.8%
12.4%
Q4 24
8.1%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
6.5%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DFLI
DFLI

Original Equipment Manufacturers$8.1M62%
Sales Channel Directly To Consumer$4.7M36%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons